Is Cue Biopharma, Inc. (CUE) Halal?
Shariah Screening — 5 Standards
Based on financial data from December 2025
| Standard | Debt Ratio | Cash Ratio | Receivables | Income | Status |
|---|---|---|---|---|---|
| AAOIFI | 32.4% / 30% | 82.1% / 30% | 3.5% / 30% | 17.47% / 5% | ✗ NOT HALAL |
| DJIM | 32.4% / 33% | 82.1% / 33% | 3.5% / 33% | 17.47% / 5% | ✗ NOT HALAL |
| MSCI | 27.6% / 33% | 69.8% / 33% | 2.9% / 33% | 17.47% / 5% | ✗ NOT HALAL |
| S&P | 32.4% / 33% | 82.1% / 33% | 3.5% / 33% | 17.47% / 5% | ✗ NOT HALAL |
| FTSE | 27.6% / 33% | 69.8% / 33% | 2.9% / 50% | 17.47% / 5% | ✗ NOT HALAL |
Financial Highlights
Profitability
| Gross Margin | -26.9% | |
| Operating Margin | 8.9% | |
| Net Margin | -96.9% | |
| Return on Equity (ROE) | -121.1% | |
| Return on Assets (ROA) | -44.6% |
Cash Flow & Balance Sheet
| Operating Cash Flow | -$22M |
| Free Cash Flow | -$22M |
| Total Debt | $4M |
| Debt-to-Equity | 15.9 |
| Current Ratio | 2.7 |
| Total Assets | $42M |
Price & Trading
| Last Close | $0.25 |
| 50-Day MA | $0.30 |
| 200-Day MA | $0.58 |
| Avg Volume | 1.8M |
| Beta | 1.6 |
|
52-Week Range
$0.22
| |
About Cue Biopharma, Inc. (CUE)
Cue Biopharma, Inc., a clinical-stage biopharmaceutical company, develops a novel class of injectable therapeutics to selectively engage and modulate targeted, disease relevant T cells in the United States. Its lead drug product candidate is the CUE-401, a bifunctional fusion protein designed to promote immune tolerance by inducing iTregs from Teff cells which is in preclinical trial; and CUE-501, a treatment of autoimmune disease via anti-viral T cell-mediated depletion of B cells. The company also develops CUE-101, which is in phase 1b clinical trial to treat HPV+ recurrent metastatic, or head and neck squamous cell carcinoma in second line, and beyond patients as a monotherapy, as well as in phase 1b clinical trial for the treatment of head and neck squamous cell carcinoma as a first line, therapy in combination with standard of care KEYTRUDA; and CUE-102, which is in phase 1b clinical trial as a monotherapy in late line recurrent metastatic WT1+ colorectal, gastric, ovarian, and pancreatic cancer. It has collaboration agreements with LG Chem, Ltd. for the development of CUE-101 and CUE-102 Immuno-STATs; collaboration and option agreement with Ono Pharmaceutical Co., Ltd to development and commercialization rights for CUE-401; and license agreement with Albert Einstein College of Medicine. The company was formerly known as Imagen Biopharma, Inc. and changed its name to Cue Biopharma, Inc. in October 2016. Cue Biopharma, Inc. was incorporated in 2014 and is headquartered in Boston, Massachusetts.
Related Halal Stocks in Healthcare
Frequently Asked Questions
Is Cue Biopharma, Inc. (CUE) halal to invest in?
Based on our screening using AAOIFI Standard 21 (the strictest methodology), Cue Biopharma, Inc. is Not Halal. The company fails one or more screening criteria. We screen against all 5 major standards: AAOIFI, DJIM, MSCI, S&P, and FTSE.
What is Cue Biopharma, Inc.'s debt ratio?
Cue Biopharma, Inc.'s debt ratio is 32.4% under the AAOIFI standard (which uses market capitalization as the denominator). The AAOIFI threshold is 30%. Under MSCI and FTSE (which use total assets as the denominator), the debt ratio is 27.6%.
What are Cue Biopharma, Inc.'s key financial metrics?
Cue Biopharma, Inc. has a market capitalization of $23M, and revenue of $27M. The company maintains a gross margin of -26.9% and a net margin of -96.9%. Return on equity stands at -121.1%.
How often is the screening data updated?
Our screening data is updated regularly using the latest available financial statements and market data. Stock prices and market caps are refreshed frequently, while financial statements are updated quarterly when companies report earnings.
Disclaimer: HalalStockGuide.com provides Shariah compliance screening for educational and informational purposes only. This is not a fatwa, financial advice, or a recommendation to buy or sell any security. Screening results are based on publicly available financial data and established methodologies. Always consult a qualified Islamic scholar and a licensed financial advisor before making investment decisions.